Verification of the Vitek Reveal System for Direct Antimicrobial Susceptibility Testing in Gram-Negative Positive Blood Cultures

被引:1
作者
Menchinelli, Giulia [1 ]
Squitieri, Damiano [2 ]
Magri, Carlotta [2 ]
De Maio, Flavio [1 ]
D'Inzeo, Tiziana [1 ,2 ]
Cacaci, Margherita [2 ]
De Angelis, Giulia [1 ,2 ]
Sanguinetti, Maurizio [1 ,2 ]
Posteraro, Brunella [2 ,3 ]
机构
[1] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Lab Ematolog, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dipartimento Sci Biotecnol Base, Clin Intensivol & Perioperatorie, I-00168 Rome, Italy
[3] Fdn Policlin Univ A Gemelli IRCCS, Unita Operativa Med Precis Microbiol Clin, Direz Sci, I-00168 Rome, Italy
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 11期
关键词
antimicrobial susceptibility testing; blood cultures; international standard for organization; verification; Vitek Reveal assay; PSEUDOMONAS-AERUGINOSA; ENTEROBACTERIACEAE;
D O I
10.3390/antibiotics13111058
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background/Objectives: The International Organization for Standardization (ISO) 20776-2:2021, which replaces ISO 20776-2:2007, focuses solely on the performance of antimicrobial susceptibility testing (AST) assays, emphasizing the ISO 20776-1 broth microdilution method as the reference standard. Consequently, categorical agreement (CA) and associated errors should not be applied. We verified the Vitek Reveal AST assay according to both ISO 20776-2:2021 and ISO 20776-2:2007 criteria. Methods: Samples from 100 simulated and clinical Gram-negative (GN) positive blood cultures (PBCs) were tested at a large teaching hospital. The simulated GN-PBCs were obtained from a hospital collection of isolates selected to represent diverse antimicrobial resistance profiles. The Reveal assay results were compared with those from the reference assay, and the time to result (TTR) for the Reveal assay was calculated. Results: The essential agreement rates were 96.1% (816/849) for simulated and 98.8% (929/940) for clinical GN-PBC samples. The bias values were -3.1 for simulated and -11.0 for clinical samples. The CA rates were 97.7% (808/827) for simulated and 99.2% (924/931) for clinical samples. The mean TTR +/- SD (hours) for resistant organisms was significantly lower (4.40 +/- 1.15) than that for susceptible, increased exposure (5.52 +/- 0.48) and susceptible (5.54 +/- 0.49) organisms. Conclusions: Our findings reinforce the potential of the Reveal assay as a valuable tool and support its implementation in clinical microbiology laboratories.
引用
收藏
页数:13
相关论文
共 23 条
  • [1] [Anonymous], 2019, 207761 ISO
  • [2] [Anonymous], 2021, Clinical Laboratory Testing and In Vitro Diagnostic Test SystemsSusceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices, P20776
  • [3] [Anonymous], 2017, REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on medical devices
  • [4] Evaluation of the Vitek® Reveal™ system for rapid antimicrobial susceptibility testing of Gram-negative pathogens, including ESBL, CRE and CRAB, from positive blood cultures
    Antonelli, Alberto
    Cuffari, Sara
    Casciato, Benedetta
    Giani, Tommaso
    Rossolini, Gian Maria
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2024, 110 (04)
  • [5] Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales
    Bartoletti, Michele
    Antonelli, Alberto
    Bussini, Linda
    Corcione, Silvia
    Giacobbe, Daniele Roberto
    Marconi, Lorenzo
    Pascale, Renato
    Dettori, Silvia
    Shbaklo, Nour
    Ambretti, Simone
    Gaibani, Paolo
    Giani, Tommaso
    Coppi, Marco
    Bassetti, Matteo
    De Rosa, Francesco Giuseppe
    Marchese, Anna
    Cavallo, Rossana
    Lewis, Russell
    Rossolini, Gian Maria
    Viale, Pierluigi
    Giannella, Maddalena
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (09) : 1290e1 - 1290e4
  • [6] Usefulness of BioFire FilmArray BCID2 for Blood Culture Processing in Clinical Practice
    Berinson, Benjamin
    Both, Anna
    Berneking, Laura
    Christner, Martin
    Luetgehetmann, Marc
    Aepfelbacher, Martin
    Rohde, Holger
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (08)
  • [7] Detection of volatile organic compounds as new paradigm to accelerate antimicrobial susceptibility testing: performance evaluation of VITEK® REVEAL™
    Bianco, Gabriele
    Boattini, Matteo
    Comini, Sara
    Bondi, Alessandro
    Curtoni, Antonio
    Piccinini, Giorgia
    Musso, Tiziana
    Broccolo, Francesco
    Cavallo, Rossana
    Nordmann, Patrice
    Costa, Cristina
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2237 - 2245
  • [8] Identification and susceptibility testing of Enterobacteriaceae and Pseudomonas aeruginosa by direct inoculation from positive BACTEC blood culture bottles into Vitek 2
    Bruins, MJ
    Bloembergen, P
    Ruijs, GJHM
    Wolfhagen, MJHM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (01) : 7 - 11
  • [9] The volatile organic compounds detection in MDR Gram-negatives antimicrobial susceptibility testing: Results from a four-month laboratory experience
    Calvo, Maddalena
    Maugeri, Gaetano
    Migliorisi, Giuseppe
    Scalia, Guido
    Stefani, Stefania
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2024, 110 (04)
  • [10] CLSI, 2016, Verification of Commercial Microbial Identification and Susceptibility Test Systems, M52 Guideline